Future Applications in ES-SCLC: Targeting DLL3 and Emerging Evidence for T-cell Engagers

Gain in-depth knowledge on the mechanism of action for T-cell–engaging therapies targeting DLL3 in extensive-stage small-cell lung cancer (ES-SCLC) and expert insights on how these agents will impact your clinical practice in this text module with accompanying slides.

Share

Program Content

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.